面颊针可改善中度抑郁症患者的抑郁和焦虑症状
一项随机对照临床试验纳入中度抑郁症患者,随机分为面颊针组、假面颊针组和药物对照组,治疗12周并随访2个月。结果显示三组HAMD-17和HAMA评分均显著下降(P<0.001),面颊针组疗效优于假面颊针组和药物组,且fMRI显示左侧额中回和左侧额上回ReHo值发生显著改变。
要点
- 面颊针可显著改善中度抑郁症患者的抑郁和焦虑症状,疗效优于假面颊针和舍曲林。
- 面颊针起效时间与假面颊针相似,但疗效持续改善至第8周后进入平台期并维持至随访。
- fMRI提示面颊针可能通过调节前额叶亚区神经活动同步性重塑认知情绪控制环路。
核心结论
- 面颊针、假面颊针和药物均能改善中度抑郁症患者的抑郁和焦虑症状严重程度,其中面颊针疗效最大。
- 面颊针可调节左侧额中回和左侧额上回的自发神经活动同步性,重塑认知与情绪控制环路的功能连接。
研究设计与样本
- 随机对照临床试验,招募符合纳入标准的中度抑郁症患者,随机分为面颊针组、假面颊针组和药物对照组。
- 面颊针组取五个标准化穴位(CA-1至CA-5),针刺深度约5-7.5 mm,共10针,留针30分钟,每周3次,治疗12周共36次。
- 假面颊针组在面颊针穴位旁开10 mm处用钝头针不透皮刺激;药物组口服舍曲林。
- 在基线、治疗后1、2、3、4、8、12周及治疗结束后2个月随访时收集HAMD-17和HAMA评分,面颊针组治疗前后进行fMRI扫描。
主要发现
- 三组HAMD-17评分均较治疗前显著下降(P<0.001),面颊针组疗效优于假面颊针组和药物组。
- 面颊针组和药物组在治疗后2个月随访时评分较治疗结束时进一步下降,面颊针组HAMD-17改善程度显著大于假面颊针组和药物组。
- 三组从治疗第2周开始出现显著变化;面颊针组在第3至4周和第4至8周评分持续显著下降,第8周后进入平台期并维持至随访。
- 三组HAMA评分均较治疗前显著下降(P<0.001),面颊针组疗效优于假面颊针组和药物组;面颊针组和假面颊针组第2周显著改善,药物组第3周开始显著改善。
- fMRI显示面颊针治疗后左侧额中回簇水平ReHo值显著降低,左侧额上回簇水平ReHo值显著升高。
临床怎么用
- 面颊针可作为中度抑郁症的潜在治疗选择,尤其适用于希望改善抑郁和焦虑症状且追求持续疗效的患者。
- 治疗频率为每周3次,共12周36次,留针30分钟,取CA-1至CA-5五个标准化穴位。
- 疗效从第2周开始显现,第8周后进入平台期,建议足疗程治疗并在治疗后2个月随访评估维持效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Through a randomized controlled clinical trial, the clinical efficacy of cheek acupuncture therapy in treating patients with moderate depressive disorder and explored its neuroimaging mechanisms was evaluated. PATIENTS AND METHODS: This clinical study recruited participants with moderate depressive disorder who met the inclusion criteria and did not meet the exclusion criteria, admitted to the outpatient clinics of Zhejiang Provincial Hospital of Traditional Chinese Medicine's Acupuncture and Mental Health Departments (September 2022 - May 2025). Participants were systematically randomized into three groups: cheek acupuncture (AC), sham-cheek acupuncture (SAC), and medication control. The AC group received acupuncture at five standardized points: Head Point (CA-1, 1 cun superior to the midpoint of the zygomatic arch), Neck Point (CA-5 at the zygomatic arch base), Upper Jiao Point (CA-2 posterior to the mandible coronoid process where it intersects the inferior border of the zygomatic arch), Middle Jiao Point (CA-3 midpoint of the line connecting Upper Jiao and Lower Jiao points), and Lower Jiao Point (CA-4 at anterior margin of the mandibular angle). The needle insertion depth was approximately 5-7.5 mm without tonification or dispersion techniques, totaling 10 needles. The SAC group selected points 10 mm lateral to the AC group points along the anterior midline of the body, using blunt-tipped needles without skin penetration. Needles were retained for 30 min. Treatment frequency: three sessions per week. Treatment duration: 12 weeks. Total treatment sessions: 36. The drug group received oral sertraline. Researchers collected HAMD-17 and HAMA scores from patients at baseline, and at 1, 2, 3, 4, 8, and 12-weeks post-treatment. and at the 2-month follow-up after completion of treatment. fMRI scans were performed on the AC group before and after treatment. Statistical analysis and efficacy assessment were conducted using SPSS (Version 25.0) and R (Version 4.3.3) statistical analysis software. RESULTS: HAMD-17 scores in the AC group, SAC group, and drug group all decreased significantly compared to pre-treatment levels (P < 0.001), indicating that all three interventions effectively improved HAMD-17 scores in patients with moderate depression. The treatment efficacy of the AC group was superior to that of the SAC group and the drug group. A comparison of the scores two months post-treatment with those immediately following treatment revealed that both the AC group and the drug group exhibited a decline in scores during the follow-up period. Notably, the degree of improvement in HAMD-17 scores in the AC group was significantly greater than that in the SAC group and the drug group, indicating that AC can alleviate depressive symptoms in patients with moderate depression. Regarding the time to onset of effect, significant changes were observed in the AC, SAC, and drug groups starting from the second week of treatment. In the AC group, scores continued to decline significantly from the third to the fourth week and from the fourth to the eighth week, entering a plateau phase after the eighth week, with the therapeutic effect maintained through the follow-up period; in the SAC and drug groups, improvements were primarily observed in the early stages of treatment and remained stable in the later stages.fMRI results showed that after cheek acupuncture treatment, ReHo values at the cluster level in the left middle frontal gyrus (L-MFG) showed significant reduction, while ReHo values at the cluster level in the left superior frontal gyrus (L-SFG) were significantly increased. The HAMA scores in the AC group, SAC group, and drug group all showed significant differences compared to pre-treatment levels (P < 0.001), indicating that all three interventions were effective in alleviating anxiety symptoms in patients with moderate depression. The AC group demonstrated superior treatment outcomes compared to the SAC group and the drug group. Regarding the time to onset of effect, both the AC group and the SAC group showed significant improvement by the second week, while the drug group began to show significant improvement by the third week. CONCLUSION: Cheek acupuncture, sham cheek acupuncture, and drug can all improve the severity of depression and anxiety symptoms in patients with moderate depression, with cheek acupuncture demonstrating the greatest efficacy. The onset of action for all three treatments is similar, but cheek acupuncture shows sustained improvement.fMRI findings revealed that cheek acupuncture modulates neural activity synchrony in distinct prefrontal subregions (middle frontal gyrus and superior frontal gyrus) through differential regulation, thereby reshaping the functional connectivity in cognitive and emotional control circuits. This neural mechanism may represent a key biological basis for its therapeutic efficacy in alleviating depressive symptoms.
引用
- Jia X, Shen P, Wang C, et al. Cheek acupuncture can improve the depressive and anxious symptoms of patients with moderate depression disorders. Complement Ther Med. 2026. PMID: 42128035. doi:10.1016/j.ctim.2026.103383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。